UPDATE: Morgan Stanley Reiterates Overweight Rating, Removes PT on Costamare Following Strong 2Q14 Results

In a report published Thursday, Morgan Stanley analyst Fotis Giannakoulis reiterated an Overweight rating on Costamare CMRE, but removed the $22.00 price target. In the report, Morgan Stanley noted, “2Q14 results well above consensus on lower expenses. CMRE reported adjusted EPS of $0.48, surpassing our $0.32 estimate and consensus' $0.38. Revenue of $124m was +7% QoQ and +22% YoY, matching our expectations, but cash expenses came 13% below our forecast with average daily costs falling 5% YoY. As a result, adjusted EBITDA of $87m (+8% QoQ, +29% YoY) beat our estimates by 5%.” Costamare closed on Wednesday at $23.44.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
date
ticker
name
Price Target
Upside/Downside
Recommendation
Firm
Posted In: Analyst ColorPrice TargetAnalyst RatingsFotis GiannakoulisMorgan Stanley
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!